Y
Yu, Jingyu
H指数:0
被引数:69
个人简介
暂无内容
教育背景
暂无内容
工作经历
暂无内容
荣誉奖项
暂无内容
FDA批准摘要: Enfortumab Vedotin联合Pembrolizumab治疗局部晚期或转移性尿路上皮癌
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2

